Compass Capital Management Inc.'s Position in Stryker Co.

Compass Capital Management Inc. has reduced its holdings in Stryker Co. (NYSE:SYK) by 1.9% during the fourth quarter, as disclosed in its latest filing with the SEC. After selling 3,256 shares, the institutional investor now owns a total of 171,604 shares of the medical technology company. Stryker accounts for about 4.0% of Compass Capital Management Inc.'s overall portfolio, positioning it as their 10th largest investment. According to the recent filing, the value of Compass Capital Management Inc.’s stake in Stryker was approximately $61,786,000.

Furthermore, other institutional investors have also made adjustments to their Stryker stakes. For instance, Parnassus Investments LLC entered a new position in Stryker shares valued at around $762,798,000 during the third quarter. International Assets Investment Management LLC significantly increased its stake by 66,967.5%, now owning 853,769 shares worth approximately $308,433,000 after acquiring an additional 852,496 shares in the last quarter. RTW Investments LP also initiated a new stake valued at approximately $143,392,000. Additionally, State Street Corp increased its holding by 2.2%, now holding 14,582,959 shares worth around $5,279,788,000 after buying an extra 316,404 shares.

Notably, FMR LLC augmented its position in Stryker by 3.0%, now possessing 7,306,994 shares valued at $2,639,725,000 after purchasing an additional 215,782 shares. Overall, approximately 77.09% of Stryker’s stock is held by hedge funds and other institutional investors.

Recent Analyst Recommendations

Several brokerage firms have recently updated their ratings on Stryker. UBS Group, for instance, raised its price target from $366.00 to $370.00 while maintaining a "neutral" rating as of October 30th. Meanwhile, Evercore ISI increased their target from $380.00 to $384.00, giving the stock an "outperform" rating. Stifel Nicolaus and Canaccord Genuity Group both also raised their price targets to $440.00 and $435.00 respectively, maintaining a "buy" rating. Additionally, Needham & Company LLC reiterated a "buy" rating with a target price of $442.00. Currently, five research analysts have a hold rating on the stock, while sixteen have rated it as a buy. According to MarketBeat data, Stryker enjoys a consensus rating of "Moderate Buy" with an average price target of $419.37.

Company Insider Activities

In related news, Stryker's CEO, Kevin Lobo, sold 57,313 shares of the company on November 7th, at an average price of $368.70, equating to a total transaction value of $21,131,303. After this transaction, he holds 100,027 shares valued at $36,879,954.90, marking a decrease of 36.43% in his position. This transaction was disclosed in an SEC filing. Additionally, Director Ronda E. Stryker sold 201,392 shares on January 31st at an average price of $392.24, resulting in a total value of approximately $78,993,998.08. Following this sale, she owns about 3,642,075 shares valued at around $1,428,567,498, representing a 5.24% decrease in her holdings. Corporate insiders currently own about 5.50% of Stryker's total stock.

Stryker's Stock Performance

As of Tuesday, Stryker's stock opened at $390.97. The company demonstrates a debt-to-equity ratio of 0.59, with quick and current ratios of 1.32 and 1.95 respectively. Over the past year, Stryker's stock has experienced a low of $314.93 and a high of $406.19. The current fifty-day moving average stands at $376.68, and the 200-day moving average is $363.22. The company has a market capitalization of $149.05 billion, with a price-to-earnings ratio of 50.38 and a price-to-earnings-growth ratio of 2.78.

Stryker Co. recently announced its earnings results on January 28th, where it reported $4.01 earnings per share for the quarter, surpassing analysts’ expectations of $3.87. The company achieved a net margin of 13.25% with a return on equity of 23.58%. Last year during the same quarter, Stryker reported earnings of $3.46 per share. Analysts presently forecast that Stryker will report earnings of 13.5 per share for the current fiscal year.

Dividend Announcement

Moreover, Stryker declared a quarterly dividend, which was disbursed on January 31st. Shareholders who were recorded on December 31st received a dividend of $0.84. The ex-dividend date was also on December 31st. This dividend payment amounts to an annualized dividend of $3.36, yielding 0.86%, marking an increase from the earlier quarterly dividend of $0.80. Currently, Stryker’s payout ratio is approximately 43.30%.

Company Overview

Stryker Corporation is a prominent player in the medical technology sector, operating through two primary segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment is known for producing implants for total joint replacements, including hips, knees, and shoulders, as well as equipment for trauma and extremities surgeries.

Stryker, Investment, Shares